N
HRMY icon

Nuveen’s Harmony Biosciences HRMY Stock Holding History

Nuveen’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.27M Sell
80,975
-2,129
-3% -$69.8K ﹤0.01% 2231
2025
Q4 		$3.11M Sell
83,104
-3,085
-4% -$101K ﹤0.01% 2117
2025
Q3 		$2.38M Sell
86,189
-5,094
-6% -$175K ﹤0.01% 2235
2025
Q2 		$2.88M Sell
91,283
-23,351
-20% -$751K ﹤0.01% 2136
2025
Q1 		$3.8M Sell
114,634
-97,717
-46% -$3.5M ﹤0.01% 2057
2024
Q4 		$7.31M Buy
212,351
+8,193
+4% +$282K ﹤0.01% 1775
2024
Q3 		$8.17M Hold
204,158
– – ﹤0.01% 1736
2024
Q2 		$6.16M Sell
204,158
-199,211
-49% -$5.99M ﹤0.01% 1841
2024
Q1 		$13.5M Buy
403,369
+677
+0.2% +$21.7K ﹤0.01% 1414
2023
Q4 		$13M Sell
402,692
-83,299
-17% -$2.33M ﹤0.01% 1419
2023
Q3 		$15.9M Buy
485,991
+79
+0% +$2.74K 0.01% 1177
2023
Q2 		$17.1M Buy
485,912
+116,784
+32% +$4.03M 0.01% 1179
2023
Q1 		$12.1M Sell
369,128
-6,874
-2% -$313K ﹤0.01% 1366
2022
Q4 		$20.7M Sell
376,002
-47,253
-11% -$2.6M 0.01% 1023
2022
Q3 		$18.7M Sell
423,255
-69,961
-14% -$3.41M 0.01% 1057
2022
Q2 		$24.1M Buy
493,216
+92,130
+23% +$4.15M 0.01% 921
2022
Q1 		$19.8M Buy
401,086
+17,092
+4% +$697K 0.01% 1206
2021
Q4 		$16.4M Sell
383,994
-77,272
-17% -$3.08M ﹤0.01% 1353
2021
Q3 		$17.7M Buy
461,266
+128,521
+39% +$4.14M 0.01% 1355
2021
Q2 		$9.39M Buy
332,745
+276,981
+497% +$8.31M ﹤0.01% 1909
2021
Q1 		$1.84M Buy
55,764
+45,607
+449% +$1.6M ﹤0.01% 2658
2020
Q4 		$367K Buy
+10,157
New +$410K ﹤0.01% 3106

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Nuveen's HRMY Position: Q1 2026 in Review

Nuveen reduced its Harmony Biosciences (HRMY) stake by 2.6% in Q1 2026, selling an estimated $69.8K and leaving 80,975 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2231.

Nuveen first reported a position in HRMY in Q4 2020 and has held it in 22 quarters since. The position peaked at $24.1M in Q2 2022. 310 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Nuveen held 80,975 shares of Harmony Biosciences worth $2.27M as of Q1 2026.
  • Nuveen sold 2,129 Harmony Biosciences shares in Q1 2026, an estimated $69.8K.
  • Harmony Biosciences made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2231 holding.
  • Nuveen first reported a position in Harmony Biosciences in Q4 2020 and has held it in 22 quarters since.
  • Nuveen's Harmony Biosciences position peaked at $24.1M in Q2 2022.
  • 310 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.